Arteriocyte is now a part of Isto Biologics.

News + Views

Blog

ISTO Technologies to Participate in Panel Session for the Regenerative Medicine Insight Track at the Biotech Showcase, January 9-11, 2012

Jan 6, 2012

January 6, 2012 – ISTO Technologies, Inc., today announced that Scott Gill, Chief Financial Officer will be participating in a panel session at the Regenerative Medicine Insight Track at the Biotech Showcase being held January 9-11, 2012 in San Francisco. Mr. Gill will discuss the state of the regenerative medicine market in the context of ISTO’s orthobiologic platform and commercialized bone graft extender substitute.
ISTO’s proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged tissue. The company believes that the two clinical-stage products currently comprising ISTO’s cell-based program, DeNovo® ET and NuQu™, potentially represent breakthrough technologies addressing two significant unmet medical needs: damaged knee cartilage and discogenic back pain. These products utilize juvenile chondrocytes that have a proven superior capacity for cartilage regeneration compared to adult cells. Additionally, ISTO’s patented cell-expansion process allows for a scalable, off-the-shelf solution not possible with autologous cell-based technologies.

 

DeNovo ET, a scaffold-free engineered cartilage tissue, is intended for the repair of damaged articular cartilage in the knee. ISTO believes the product represents a novel treatment for cartilage repair. DeNovo ET is developed in partnership with Zimmer, Inc.

 

NuQu is an injectable juvenile chondrocyte therapy for early intervention and restoration of disc function in patients suffering from discogenic back pain. There is currently no effective treatment for intervertebral disc repair and this minimally-invasive ambulatory treatment potentially represents a breakthrough and cost-effective solution for discogenic back pain.

 

In addition to ISTO’s cell-based cartilage programs, the company is currently producing and marketing, InQu®, a bone graft extender and substitute. InQu combines integrated hyaluronic acid and a synthetic polymer for better handling and biology. The primary target market for the product is spinal fusion applications. InQu has been used in over 12,000 surgeries at U.S. hospitals to date.

 

The following are specific details regarding ISTO Technologies’ participation at the conference:
Regenerative Medicine Insight Track at the Biotech Showcase:
Date: January 10, 2012
Time: 4:20 – 5:45PM
Panel: Therapeutic Focus Track: Tissue Engineering, Orthobiologics and Artificial Conduits to Wound Care and BioPrinting
Location: Parc 55 Wyndham, 55 Cyril Magnin Street, San Francisco, CA
About the Regenerative Medicine Insight Track:
This event was developed by the Alliance for Regenerative Medicine, and will be held as part of the Biotech Showcase 2012 conference. The meeting will start with the Second Annual State of the Industry Briefing, followed by a series of analyst-led panels focused on therapeutic areas where regenerative medicine holds great promise. The State of the Industry briefing is open to the public, but attendance at the disease panels will require registration for individuals without press or investor credentials.

 

About ISTO
ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istobiologics.com.

To top